Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
In this randomised, double blind, 2x2 factorial placebo-controlled trial, Dr David Lowe and colleagues investigate the impact of early antiviral therapy in COVID-19.
United Kingdom City Of Norgen Biotek United Kingdom Medical Research Council Rosetrees Foundation Trial Steering Committee
Source: plos.org